Tongmai Yangxin Pill (TMYX) containing CP(Fan et al., 2021) is effective in treating cardiovascular diseases by increasing the expression of ESR1, blocking the reduction of IκBα level and the phosphorylation of IKKα/β, IκBα, and NF-κB p65, and inhibiting the production of IL-6 and TNF-α, and exerting anti-inflammatory effects (Chen et al., 2020; 2020). The gene discussed is NFKB1; the disease is cardiovascular disorder.